CPA
WVE icon

Capital Performance Advisors’s Wave Life Sciences WVE Stock Holding History

Capital Performance Advisors’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-13
Closed -$107 – 2727
2024
Q3 		$107 Buy
+13
New +$78 ﹤0.01% 2685

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Capital Performance Advisors's WVE Position: Q4 2024 in Review

Capital Performance Advisors sold out of Wave Life Sciences (WVE) in Q4 2024, closing a stake of 13 shares — an estimated $107 sold.

Capital Performance Advisors first reported a position in WVE in Q3 2024 and held it in 1 quarter. The position peaked at $107 in Q3 2024. 183 funds tracked by Wall St. Rank hold WVE as of Q4 2024.

  • Capital Performance Advisors reported no remaining Wave Life Sciences position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 13 Wave Life Sciences shares in Q4 2024, an estimated $107.
  • Capital Performance Advisors first reported a position in Wave Life Sciences in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Wave Life Sciences position peaked at $107 in Q3 2024.
  • 183 funds tracked by Wall St. Rank held Wave Life Sciences as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.